The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Glioblastoma Multiforme Treatment (GBM) Market Research Report 2024
Synopsis
The global Glioblastoma Multiforme Treatment (GBM) market was valued at US$ 548.3 million in 2023 and is anticipated to reach US$ 996.4 million by 2030, witnessing a CAGR of 8.8% during the forecast period 2024-2030.
North American market for Glioblastoma Multiforme Treatment (GBM) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Glioblastoma Multiforme Treatment (GBM) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Glioblastoma Multiforme Treatment (GBM) in Hospital & Clinic is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Glioblastoma Multiforme Treatment (GBM) include Merck, Teva Pharmaceutical, Arbor Pharmaceuticals, Sun Pharmaceutical and Roche, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Glioblastoma Multiforme Treatment (GBM), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glioblastoma Multiforme Treatment (GBM).
Report Scope
The Glioblastoma Multiforme Treatment (GBM) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Glioblastoma Multiforme Treatment (GBM) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glioblastoma Multiforme Treatment (GBM) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Teva Pharmaceutical
Arbor Pharmaceuticals
Sun Pharmaceutical
Roche
Segment by Type
Chemotherapy
Radiotherapy
Gene therapy
Molecular biotechnology
Segment by Application
Hospital & Clinic
ASCs
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Glioblastoma Multiforme Treatment (GBM) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Glioblastoma Multiforme Treatment (GBM) market was valued at US$ 548.3 million in 2023 and is anticipated to reach US$ 996.4 million by 2030, witnessing a CAGR of 8.8% during the forecast period 2024-2030.
North American market for Glioblastoma Multiforme Treatment (GBM) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Glioblastoma Multiforme Treatment (GBM) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Glioblastoma Multiforme Treatment (GBM) in Hospital & Clinic is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Glioblastoma Multiforme Treatment (GBM) include Merck, Teva Pharmaceutical, Arbor Pharmaceuticals, Sun Pharmaceutical and Roche, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Glioblastoma Multiforme Treatment (GBM), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glioblastoma Multiforme Treatment (GBM).
Report Scope
The Glioblastoma Multiforme Treatment (GBM) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Glioblastoma Multiforme Treatment (GBM) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glioblastoma Multiforme Treatment (GBM) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Teva Pharmaceutical
Arbor Pharmaceuticals
Sun Pharmaceutical
Roche
Segment by Type
Chemotherapy
Radiotherapy
Gene therapy
Molecular biotechnology
Segment by Application
Hospital & Clinic
ASCs
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Glioblastoma Multiforme Treatment (GBM) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Glioblastoma Multiforme Treatment (GBM) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chemotherapy
1.2.3 Radiotherapy
1.2.4 Gene therapy
1.2.5 Molecular biotechnology
1.3 Market by Application
1.3.1 Global Glioblastoma Multiforme Treatment (GBM) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital & Clinic
1.3.3 ASCs
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Glioblastoma Multiforme Treatment (GBM) Market Perspective (2019-2030)
2.2 Glioblastoma Multiforme Treatment (GBM) Growth Trends by Region
2.2.1 Global Glioblastoma Multiforme Treatment (GBM) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Glioblastoma Multiforme Treatment (GBM) Historic Market Size by Region (2019-2024)
2.2.3 Glioblastoma Multiforme Treatment (GBM) Forecasted Market Size by Region (2025-2030)
2.3 Glioblastoma Multiforme Treatment (GBM) Market Dynamics
2.3.1 Glioblastoma Multiforme Treatment (GBM) Industry Trends
2.3.2 Glioblastoma Multiforme Treatment (GBM) Market Drivers
2.3.3 Glioblastoma Multiforme Treatment (GBM) Market Challenges
2.3.4 Glioblastoma Multiforme Treatment (GBM) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Glioblastoma Multiforme Treatment (GBM) Players by Revenue
3.1.1 Global Top Glioblastoma Multiforme Treatment (GBM) Players by Revenue (2019-2024)
3.1.2 Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Players (2019-2024)
3.2 Global Glioblastoma Multiforme Treatment (GBM) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Glioblastoma Multiforme Treatment (GBM) Revenue
3.4 Global Glioblastoma Multiforme Treatment (GBM) Market Concentration Ratio
3.4.1 Global Glioblastoma Multiforme Treatment (GBM) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Glioblastoma Multiforme Treatment (GBM) Revenue in 2023
3.5 Glioblastoma Multiforme Treatment (GBM) Key Players Head office and Area Served
3.6 Key Players Glioblastoma Multiforme Treatment (GBM) Product Solution and Service
3.7 Date of Enter into Glioblastoma Multiforme Treatment (GBM) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Glioblastoma Multiforme Treatment (GBM) Breakdown Data by Type
4.1 Global Glioblastoma Multiforme Treatment (GBM) Historic Market Size by Type (2019-2024)
4.2 Global Glioblastoma Multiforme Treatment (GBM) Forecasted Market Size by Type (2025-2030)
5 Glioblastoma Multiforme Treatment (GBM) Breakdown Data by Application
5.1 Global Glioblastoma Multiforme Treatment (GBM) Historic Market Size by Application (2019-2024)
5.2 Global Glioblastoma Multiforme Treatment (GBM) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Glioblastoma Multiforme Treatment (GBM) Market Size (2019-2030)
6.2 North America Glioblastoma Multiforme Treatment (GBM) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2019-2024)
6.4 North America Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Glioblastoma Multiforme Treatment (GBM) Market Size (2019-2030)
7.2 Europe Glioblastoma Multiforme Treatment (GBM) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2019-2024)
7.4 Europe Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Market Size (2019-2030)
8.2 Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Market Size by Region (2019-2024)
8.4 Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Glioblastoma Multiforme Treatment (GBM) Market Size (2019-2030)
9.2 Latin America Glioblastoma Multiforme Treatment (GBM) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2019-2024)
9.4 Latin America Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Size (2019-2030)
10.2 Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2019-2024)
10.4 Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Glioblastoma Multiforme Treatment (GBM) Introduction
11.1.4 Merck Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024)
11.1.5 Merck Recent Development
11.2 Teva Pharmaceutical
11.2.1 Teva Pharmaceutical Company Detail
11.2.2 Teva Pharmaceutical Business Overview
11.2.3 Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Introduction
11.2.4 Teva Pharmaceutical Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024)
11.2.5 Teva Pharmaceutical Recent Development
11.3 Arbor Pharmaceuticals
11.3.1 Arbor Pharmaceuticals Company Detail
11.3.2 Arbor Pharmaceuticals Business Overview
11.3.3 Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Introduction
11.3.4 Arbor Pharmaceuticals Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024)
11.3.5 Arbor Pharmaceuticals Recent Development
11.4 Sun Pharmaceutical
11.4.1 Sun Pharmaceutical Company Detail
11.4.2 Sun Pharmaceutical Business Overview
11.4.3 Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Introduction
11.4.4 Sun Pharmaceutical Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024)
11.4.5 Sun Pharmaceutical Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Glioblastoma Multiforme Treatment (GBM) Introduction
11.5.4 Roche Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024)
11.5.5 Roche Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
